COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines

Table 3

Variables and outcomes.

	ICU survivors (n = 54)	ICU nonsurvivors (n = 37)	Significance
Demographics
Age (years)	66 (±15)	63 (±13)	0.253
Gender (% of males)	61.1%	64.9%	0.826
SAPS-3	47 (±13)	60 (±17)	<0.001
SARS-CoV-2 status			<0.001
Positive	9 (16.7%)	22 (59.5%)
Negative	45 (83.3%)	15 (40.5%)
Comorbidities
Neurologic			0.003
Yes	14 (25.9%)	1 (2.7%)
No	40 (74.1%)	36 (97.3%)
Cardiovascular			0.440
Yes	44 (81.5%)	27 (73%)
No	10 (18.5%)	10 (27%)
Pulmonary			0.821
Yes	17 (31.5%)	13 (35.1%)
No	37 (68.5%)	24 (64.9%)
Renal			0.039
Yes	22 (40.7%)	7 (18.9%)
No	32 (59.3%)	30 (81.1%)
Endocrine			0.831
Yes	23 (42.6%)	17 (45.9%)
No	31 (57.4%)	20 (54.1%)
Autoimmune			0.302
Yes	7 (13%)	2 (5.4%)
No	47 (87%)	35 (94.6%)
Malignancy			0.344
Yes	5 (9.3%)	6 (16.2%)
No	49 (90.7%)	31 (83.8%)
Laboratories on ICU admission
Hemoglobin (g/L)	120 (±30)	131 (±23)	0.050
WBC count (×10^3/µL)	12.7 (±10)	9.5 (±5)	0.081
Platelets (×10^9/L)	231 (±91)	232 (±110)	0.952
PF ratio	258 (±145)	166 (±99)	0.003
Lactate (mmol/L)	2.7 (±2.2)	2.4 (±1.8)	0.537
Treatment strategy
Hydroxychloroquine			<0.001
Yes	12 (22.2%)	22 (59.5%)
No	42 (77.8%)	15 (40.5%)
Tocilizumab			0.008
Yes	6 (11.1%)	13 (35.1%)
No	48 (88.9%)	24 (64.9%)
Lopinavir/ritonavir			0.017
Yes	1 (1.9%)	6 (16.2%)
No	53 (98.1%)	31 (83.8%)
CRRT			<0.001
Yes	8 (14.8%)	20 (54.1%)
No	46 (85.2%)	17 (45.9%)
NMBA			0.007
Yes	1 (1.9%)	7 (18.9%)
No	53 (98.1%)	30 (81.1%)
Prone positioning			0.023
Yes	4 (7.4%)	12 (32.4%)
No	50 (92.6%)	25 (67.6%)
IVIG			0.564
Yes	1 (1.9%)	2 (5.4%)
No	53 (98.1%)	35 (94.6%)
HA-330			0.058
Yes	2 (3.7%)	6 (16.2%)
No	52 (96.3%)	31 (83.6%)
Intubation			<0.001
Yes	27 (50%)	36 (97.3%)
No	27 (50%)	1 (2.7%)
Others
Number of days intubated	12 (±8)	9 (±7)	0.111